Following deep cuts, Yumanity strikes a deal to sell drugs to J&J, hands the keys to Genentech-partnered Kineta

Yumanity has found that “strategic alternative” it started searching for early this year as its share price shriveled, forcing deep staff cuts.

The suffering biotech has agreed to sell off most of its pipeline — including a partially-held Phase I Parkinson’s drug and unpartnered discovery-stage neuroscience product candidates — to...

Click to view original post